Table 1.
Patient- and eye-specific characteristics at the time of the first periocular depot corticosteroid injection
| Person-specific characteristics | Anterior uveitis | Intermediate uveitis | Posterior or Panuveitis | Total |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | |
| Number of patients | 286 (31.3%) | 304 (33.3%) | 324 (35.4%) | 914 |
| Age at diagnosis, years (range) | 37.9 (0-84) | 32.4 (4.6-80.5) | 41.6 (2.9-82.7) | 37.4 (0-84) |
| Sex (% male) | 92 (32.2%) | 104 (34.2%) | 103 (31.8%) | 299 (32.7%) |
| Race/ethnicity | ||||
| White | 191 (66.8%) | 241 (79.3%) | 213 (65.7%) | 645 (70.6%) |
| Black | 68 (23.8%) | 31 (10.2%) | 71 (21.9%) | 170 (18.6%) |
| Hispanic/Native American | 7 (2.4%) | 10 (3.3%) | 14 (4.3) | 31 (3.4%) |
| Other | 20 (7.0%) | 22 (7.2%) | 26 (8.0%) | 68 (7.4%) |
| Duration, years (range) | 5.4 (0-33.3) | 4.2 (0-27.3) | 4.9 (0-36.3) | 4.8 (0-36.3) |
| Bilateral uveitis | 199 (69.6%) | 251 (82.6%) | 281 (86.7%) | 731 (80.0%) |
| Systemic Therapy* | ||||
| Systemic corticosteroids | 12 (4.2%) | 25 (9.1%) | 28 (8.9%) | 65 (7.5%) |
| Systemic immunosuppressives | 7 (2.5%) | 10 (3.6%) | 14 (4.5%) | 31 (3.6%) |
| Neither | 263 (93.3%) | 239 (87.2%) | 271 (86.6%) | 773 (89.0%) |
| Eye-specific characteristics | ||||
| Eyes that received ≥1 periocular corticosteroid injection | 359 | 397 | 436 | 1192 |
| Eyes that received ≥2 injections | 154/354 (43.5%) | 211/397 (53.1%) | 224/435 (51.5%) | 589/1186 (49.7%) |
| Presence of any ocular complication** | 225/354 (63.6%) | 269/396 (67.9%) | 267/431 (61.9%) | 761/1181 (64.4%) |
| Ocular hypertension | ||||
| ≥ 24 mm Hg | 28/342 (8.2%) | 24/380 (6.3%) | 33/411 (8.0%) | 85/1133 (7.5%) |
| ≥ 30 mm Hg | 3/342 (0.9%) | 1/380 (0.3%) | 4/411 (1.0%) | 8/1133 (0.7%) |
| IOP≤ 7mmHg | 8/334 (2.4%) | 2/379 (0.5%) | 17/408 (4.2%) | 27/1121 (2.4%) |
| Prior glaucoma surgery | 19/354 (5.4%) | 5/397 (1.2%) | 19/435 (4.4%) | 43/1186 (3.6%) |
| Prior cataract surgery | 118/348 (33.9%) | 45/392 (11.4%) | 115/422 (27.2%) | 278/1162 (23.9%) |
| Cataract causing VA worse than 20/40 | 14/354 (4.0%) | 16/397 (4.0%) | 28/434 (6.4%) | 58/1185 (4.9%) |
| Macular edema | 116/289 (40.1%) | 209/369 (56.6%) | 151/372 (40.6%) | 476/1030 (46.2%) |
| Macular edema causing VA worse than 20/40*** | 68/289 (23.5%) | 103/369 (27.9%) | 80/372 (21.5%) | 251/1030 (24.4%) |
| Inflammatory activity | ||||
| Non-missing total | 353 | 392 | 421 | 1166 |
| Inactive | 71 (20.1%) | 53 (13.5%) | 78 (18.5%) | 202 (17.3%) |
| Slightly active | 30 (8.5%) | 38 (9.7%) | 46 (10.9%) | 114 (9.8%) |
| Active | 252 (71.4%) | 301 (76.8%) | 297 (70.5%) | 850 (72.9%) |
| Visual acuity | ||||
| Non-missing total | 354 | 397 | 434 | 1185 |
| 20/40 or better | 136 (38.4%) | 144 (36.3%) | 119 (27.4%) | 399 (33.7%) |
| 20/50 to 20/200 | 120 (33.9%) | 167 (42.1%) | 169 (38.9%) | 456 (38.5%) |
| 20/200 or worse | 98 (27.7%) | 86 (21.7%) | 146 (33.6%) | 330 (27.8%) |
Systemic therapy at the time of first periocular injection. Systemic immunosuppressives include those using systemic immunosuppressives in combination with systemic corticosteroids (there were only 4 such cases: 2 each in the anterior and intermediate uveitis groups).
In addition to the complications listed subsequently in the table, “any ocular complication” includes band keratopathy, peripheral synechiae, posterior synechiae, hypotony, ocular hypertension or glaucoma, history of cataract or glaucoma surgery, retinal vasculitis, macular edema, epiretinal membrane, exudative retinal detachment, pre-retinal or choroidal neovascularization.
Eyes with visual acuity worse than 20/40 where macular edema was recorded as the primary cause of visual acuity loss at the time of first periocular corticosteroid injection.